The chemotherapeutic drug doxorubicin does not exacerbate p16Ink4a-positive senescent cell accumulation and cardiometabolic disease development in young adult female LDLR-deficient mice.
Toxicol Appl Pharmacol
; 468: 116531, 2023 06 01.
Article
in En
| MEDLINE
| ID: mdl-37088304
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cardiovascular Diseases
/
Cyclin-Dependent Kinase Inhibitor p16
Limits:
Animals
Language:
En
Journal:
Toxicol Appl Pharmacol
Year:
2023
Type:
Article
Affiliation country:
Netherlands